| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
| Urinary tract infections in adults | QS90 | | |
| Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy | MIB316 | | |
| Antenatal care | QS22 | | |
| Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | NG231 | | |
| Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Transvenous obliteration for gastric varices | IPG751 | | |
| Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer | IPG752 | | |
| Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
| Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia | MIB315 | | |
| Delirium: prevention, diagnosis and management in hospital and long-term care | CG103 | | |
| Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
| Trabeculectomy with a biodegradable collagen matrix implant for glaucoma | IPG750 | | |
| Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy | MIB314 | | |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
| Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education | NG213 | | |
| MRI-based technologies for assessing non-alcoholic fatty liver disease | DG50 | | |
| Transcutaneous electrical stimulation of the trigeminal nerve for ADHD | IPG748 | | |
| Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease | IPG749 | | |
| Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
| Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
| PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis | MIB313 | | |
| Chronic heart failure in adults | QS9 | | |
| Diabetes in pregnancy | QS109 | | |
| Hip fracture: management | CG124 | | |
| Hip fracture in adults | QS16 | | |
| Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain | IPG747 | | |
| Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
| Thyroid cancer: assessment and management | NG230 | | |
| Tobacco: treating dependence | QS207 | | |
| Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
| Fetal monitoring in labour | NG229 | | |
| Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Esketamine nasal spray for treatment-resistant depression | TA854 | | |
| PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes | MIB312 | | |
| Memokath 051 Ureter stent for ureteric obstruction | MTG75 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Optilume for treating recurrent bulbar urethral strictures | MTG73 | | |
| GreenLight XPS for treating benign prostatic hyperplasia | MTG74 | | |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |